Lead Product(s) : Zibotentan,Dapagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zibotentan/dapagliflozin combination leverages SGLT2 inhibition and high selectivity ETA receptor antagonism. It is being evaluated in phase 2 clinical trials for the treatment of chronic kidney disease and proteinuria.
Product Name : ZD4054
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2023
Lead Product(s) : Zibotentan,Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Oxide Adipate
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shield Therapeutics PT20 Paper Publication
Details : PT20 is a novel iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia (when there is too much phosphorus present in the blood) related to dialysis or non-dialysis dependent chronic kidney disease (CKD).
Product Name : PT20
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Ferric Oxide Adipate
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable